Pharmacokinetic properties:

Following intravenous injection of a single dose of Hadid containing 100 mg iron in healthy volunteers, maximum iron levels, averaging 538 µmol/l, were obtained 10 min after Special precautions for storage: injection. The volume of distribution of the central compartment corresponded well to the volume of plasma (approx. 3L). The iron injected was rapidly cleared from the plasma, the terminal halflife being approx. 6 h. The volume of distribution at steady state was about 8L, indicating a low iron distribution in the body fluid. Due to the lower stability of iron sucrose in comparison to Instructions for use/handling: transferrin, a competitive exchange of iron to transferrin was Ampoules should be visually inspected for sediment and damage observed. This resulted in iron transport of approx.31mg before use. Only those with sediment free and homogenous iron/24 h.

Renal elimination of iron, occurring in the first 4 h after injection, corresponds to less than 5% of the total body clearance. After 24 h the plasma levels of iron were reduced to the pre-dose iron level Ampoules (5 ml) containing 100 mg of iron: 5 and about 75% of the dosage of sucrose was excreted.

Preclinical safety data:

Preclinical data showed no special hazards based on conventional studies of repeated toxicity, genotoxicity and toxicity to reproduction in animals.

PHARMACEUTICAL PARTICULARS:

List of excipients

Water for injection and sodium hydroxide.

Incompatibilities

Hadid must only be mixed with 0.9%w/v NaCl solution.

No other intravenous dilution solutions and therapeutic agent should be used as there is the potential for precipitation and/or interaction.

The compatibility with containers other than glass, polyethylene and PVC is not known.

Shelf life


Shelf-life in the product as packaged for sale: 2 years.

Shelf-life after first opening the container:

From a microbiological point of view, the product should be used immediately.

Shelf-life after dilution with 0.9% sodium chloride solution:

Chemical and physical in-use stability has been demonstrated for 12 hours at room temperature. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and



Store in original carton. Store at 15-30°C.


Nature and contents of container

Type I glass ampoules with extractable volumes of 5ml.

solutions must be used. See also "Shelf life".

Package form:







INJECTION

Hadid

Iron Sucrose

PHARMACEUTICAL FORM:

CLINICAL PARTICULARS

Therapeutic indications

preparations are ineffective.

Posology and method of administration:

following indications:

noncompliant.

Administration.

one complete infusion.

Infusion:

QUALITATIVE AND QUANTITATIVE COMPOSITION:

pH of 10.5-11.0 and an osmolarity of 1250 mOsmol/l.

Where there is a clinical need for a rapid iron supply:-

corresponding to 100 mg iron per ampoule.

Each 5ml ampoule contains 20mg/ml iron as iron sucrose

Solution for injection or concentrate for solution for infusion.

Hadid is a dark brown, non-transparent, aqueous solution with a

Hadid is indicated for the treatment of iron deficiency in the

In patients who cannot tolerate oral iron therapy or who are

In active inflammatory bowel disease where oral iron

Hadid has exclusively to be administered intravenously by drip

infusion, by slow injection or directly into the venous limb of the

dialyser and is not suitable for intramuscular use and for total

Before administration of the first therapeutic dose, a test dose

should be given. If any allergic reactions or intolerance occurs

during administration, the therapy must be stopped immediately.

Hadid should preferably be administered by drip infusion (in

order to reduce the risk of hypotensive episodes and paravenous

injection) in a dilution of 1ml Hadid (20mg iron) in max. 20ml 0.9% w/v sodium chloride [5ml (100mg iron) in max. 100ml 0.9% w/v

NaCl e.t.c up to 25ml (500mg iron) in max. 500ml 0.9% w/v NaCl].

Dilution must take place immediately prior to infusion and the

solution should be administered as follows: 100mg iron in at least 15 minutes; 200mg iron in at least 30 minutes; 300mg iron in at

least 1.5 hours; 400mg iron in at least 2.5 hours and 500 mg iron in

at least 3.5 hours. For the administration of the maximum

tolerated single dose of 7mg iron/kg body weight, an infusion

time of at least 3.5 hours has to be respected, independently of

the total dose. Total number of Hadid ampoules to be administered

	Body weight																	
	5kg	10kg	15kg	20kg	25kg	30kg	35kg	40kg	45kg	50kg	55kg	60kg	65kg	70kg	75kg	80kg	85kg	90kg
Hb 60 g/L	1.5	3	5	6.5	8	9.5	12.5	13.5	15	16	17	18	19	20	21	22.5	23.5	24.5
Hb 75 g/L	1.5	3	4.5	5.5	7	8.5	11.5	12	13	14	15	16	16.5	17.5	18.5	19.5	20.5	21.5
Hb 90 g/L	1.5	2.5	3.5	5	6	7.5	10	11	11.5	12	13	13.5	14.5	15	16	16.5	17	18
Hb 105 g/L	1	2	3	4	5.5	6.5	9	9.5	10	10.5	11	11.5	12	12.5	13	13.5	14	14.5

If the total necessary dose exceeds the maximum allowed single dose, then the administration has to be split. If no response of the haematological parameters is observed after I to 2 weeks the original diagnosis should be reconsidered.

Calculation of dosage for iron replacement secondary to blood loss and to support autologous blood donation:

The required Hadid dose to compensate the iron deficit is calculated according to the following formulas:

If the quantity of blood lost is known: The administration of 200 mg I.V iron (=10 ml Hadid) results in an increase in haemoglobin which is equivalent to 1 unit blood (= 400ml with 150 g/L Hb content).

Iron to be replaced [mg] = number of blood units lost x 200 or Amount of Hadid needed (ml) = number of blood units lost x 10 If the Hb level is reduced: use the previous formula considering

that the depot iron does not need to be restored. Iron to be replaced [mg] = body weight [kg] x 0.24 x (target Hb-

actual Hb) [g/L] e.g.: body weight 60kg, Hb deficit = 10 g/L = iron to be replaced ≅ 150mg => 7.5ml Hadid needed.

dose infusion (TDI), where the full dose of iron required, Normal posology (representing the patient's total iron deficit) is administered in

Adults and the Elderly:

5-10 ml Hadid (100-200mg iron) once to three times a week depending on the haemoglobin level.

Children:

There is limited data on children under study conditions. If there is a clinical need, it is recommended not to exceed 0.15 ml Hadid (3mg iron) per kg bw once to three times per week depending on the haemoglobin level.

Maximum tolerated single dose Adults and the Elderly:

As injection: 10ml Hadid (200mg iron) injected over at least 10 minutes.

As infusion:

When the clinical situation demanded, doses of up to 500mg have been administered. The maximum tolerated single dose is 7mg iron per kg body weight given once per week, but not exceeding 500mg iron. For administration time and dilution ratio see section

"Administration"

Before administration of the therapeutic dose in a new patient the first 20mg iron in adults and in children with a body weight greater than 14 kg and half the daily dose (1.5mg iron/kg) in **Contra-indications:** children with a body weight less than 14 kg should be infused over The use of Hadid is contra-indicated in cases of: 15 minutes as a test dose. If no adverse reactions occur, the -anaemia not caused by iron deficiency. remaining portion of the infusion can be administered at recommended speed.

Intravenous injection:

Hadid can also be administered undiluted by slow intravenous injection at the (normal) recommended rate of 1 ml Hadid (20mg Special warnings and special precautions for use: iron) per minute [5ml Hadid (100 mg iron) in at least 5 minutes]. A injection.

Before administration of the therapeutic dose in a new patient a test dose of 1 ml Hadid (20mg iron) in adults and in children with a body weight greater than 14 kg and half the daily dose (1.5 mg iron/kg) in children with a body weight less than 14 kg should be case of a mild allergic reaction, antihistamines should be injected over 1 to 2 minutes. If no adverse reactions occur within a administered: in the case of a serious anaphylactoid reaction waiting period of 15 minutes, the remaining portion of the adrenaline should be administered immediately. Facilities for injection can be administered at recommended speed. After an cardio-pulmonary resuscitation must be available. injection the arm of the patient should be extended.

Injection into dialyser:

Hadid may be administered directly into the venous limb of the dialyser under the same conditions as for intravenous injection.

Dosage

Calculation of dosage:

The dosage has to be individually adapted according to the total iron deficit calculated with the following formula:

Total iron deficit [mg] = body weight [kg] x (target Hb—actual Hb) g/L1x0.24*+depotiron[mg]

Below to 35 kg body weight target Hb = 130g/L resp. depot iron = 15mg/kg body weight 35kg body weight and above: target Hb = 150g/Lresp.depotiron = 500mg

*Factor 0.24 = 0.0034 x 0.07 x 1000 (Iron content of haemoglobin 0.34%/Blood volume ≅ 7% of body weight/Factor 1000)= Hypotensive episodes may occur if injection is administered too (conversion from "g" to "mg")

Total amount of Hadid to be administered (in ml) =

Total iron deficit [mg] 20 mg/ml.

(1 ampoule of Hadid corresponds to 5ml)

A higher incidence of adverse reactions (in particular hypotension, which can also be more severe, is associated with Interaction with other medicaments and other forms of higher dosages.

must be strictly adhered to, even if the patient does not receive the maximum tolerated single dose.

-Iron overload or disturbances in utilization of iron, -known hypersensitivity to Hadid or any of its inactive components. - Pregnancy first Trimester.

Hadid should only be administered where the indication is maximum of 10 ml Hadid (200mg iron) can be injected per confirmed by appropriate investigations (e.g. serum ferritin, or haemoglobin (Hb) or haematocrit or erythrocyte count. Or red cell indices — MCV. MCH. MCHC.

> Parenterally administered iron preparations can cause allergic or anaphylactoid reactions, which can be potentially lethal. In the

> In patients with a history of asthma, eczema, other atopic allergies or allergic reactions to other parenteral iron preparations and patients with low iron binding capacity and/or folic acid deficiency Hadid should be administered with care as they are particularly at risk of an allergic reaction. However it was shown in a study with a limited number of iron dextran sensitive patients that Hadid could be administered with no complications.

> Hadid should be administered with care in patients with liver dysfunction.

> Hadid must be used with care in patients with acute or chronic infection who have excessive ferritin values as parenterally administered iron can unfavourably influence a bacterial or viral infection.

> rapidly.

Paravenous leakage must be avoided because leakage of Hadid at the injection site may lead to pain, inflammation, tissue necrosis, sterile abscess and brown discoloration of the skin.

interaction:

Therefore the infusion times given in section "Administration" As with all parenteral iron preparations, Hadid should not be

administered concomitantly with oral iron preparations since the absorption of oral iron is reduced. Therefore an oral iron therapy **Gastrointestinal disorders:** should at least be started 5 days after the last injection.

Pregnancy and Lactation:

Data on a limited number of exposed pregnancies indicated no adverse effects of Iron Sucrose on pregnancy or on the health of the foetus/newborn child. No well-controlled studies in pregnant Musculoskeletal, connective tissue and bone disorders: women are available to date. Animal studies do not indicate Uncommon: muscle cramps, myalgia. direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal General disorders and administration site disorders development.

Nevertheless, risk/benefit evaluation is required.

Non metabolised Iron Sucrose is unlikely to pass into the mother's Rare: anaphylactoid reactions (rarely involving arthralgia); milk. Therefore, Hadid should not present a risk to the suckling peripheral oedema; fatigue, asthenia; malaise. child.

Effects on ability to drive and use machines:

It is unlikely that Hadid has an influence on the ability to drive and use machines.

Undesirable effects:

The most frequently reported adverse drug reactions (ADRs) of Hadid in clinical trials were transient taste perversion, hypotension, fever and shivering, injection site reactions and nausea, occurring in 0.5 to 1.5% of the patients. Non-serious **Overdose:** anaphylactoid reactions occurred rarely.

In general anaphylactoid reactions are potentially the most serious adverse reactions (see "Special warnings and Precautions Overdosage should be treated with supportive measures and, if for use").

In clinical trials, the following adverse drug reactions have been **PHARMACOLOGICAL PROPERTIES:** reported in temporal relationship with the administration of Hadid, with at least a possible causal relationship:

Nervous system disorders:

Common (greater than or equal to 1% and less than 10%): transient taste perversions (in particular metallic taste).

Uncommon (greater than or equal to 0.1% and less than 1%): The iron in the polynuclear cores is bound in a similar structure as headache; dizziness. Rare (greater than or equal to 0.01% and less in the case of physiologically occurring ferritin. than 0.1%): paraesthesia.

Cardio-vascular disorders:

palpitations.

Respiratory, thoracic and mediastinal disorders Uncommon: bronchospasm, dyspnoea.

Uncommon: nausea: vomiting: abdominal pain: diarrhoea.

Skin and subcutaneous tissue disorders:

Uncommon: pruritus: urticaria: rash. exanthema. erythema.

Uncommon: fever, shivering, flushing; chest pain and tightness. Injection site disorders such as superficial phlebitis, burning, swelling.

Moreover, in spontaneous reports the following adverse reactions have been reported:

Isolated cases: reduced level of consciousness, light-headed feeling, confusion, angioedema and swelling of joints.

Paravenous leakage must be avoided because leakage of Hadid at the injection site may lead to pain, inflammation, tissue necrosis, sterile abscess and brown discoloration of the skin.

Overdosage can cause acute iron overloading which may manifest itself as haemosiderosis.

required, an iron chelating agent.

The polynuclear iron(III)-hydroxide cores are superficially surrounded by a large number of non-covalently bound sucrose molecules resulting in a complex whose molecular mass MW is approx. 43 kDa. This is sufficiently large to prohibit renal elimination. The resulting complex is stable and does not release ionic iron under physiological conditions.

Pharmacodynamic properties:

The ferrokinetics of Hadid labelled with ⁵⁹Fe and ⁵²Fe were Uncommon: hypotension and collapse; tachycardia and assessed in 6 patients with anaemia and chronic renal failure. Plasma clearance of ⁵²Fe was in the range of 60 to 100 minutes. ⁵²Fe was distributed to the liver, spleen and bone marrow. At two to four weeks after administration, the maximum red blood cell utilisation of ⁵⁹Fe ranged from 68% to 97%.